OTLK Reports $0 Revenue, $0 EPS, Updates FDA Meeting on ONS-5010/LYTENAVA™ CRL, Phase 3 NORSE TWO Meets Endpoints, Seeks Approval Pathways
Outlook Therapeutics, Inc. Common Stock · Now $0.73
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS